Bradley van Paridon

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

The week 96 results of the DRIVE-AHEAD phase 3 noninferiority trial support noninferiority of doravirine to efavirenz in treatment-naive adults with HIV-1.